Meet us at the 14th Dresden Symposium on Autoantibodies taking place from September 10 to September 13, 2019! The main topic of the upcoming symposium deals with the role of autoantibodies in precision health and precision medicine. Further topics: ★ Autoantibodies in systemic and organ specific autoimmune diseases (induction, pathology, clinical relevance) ★ Novel autoantibodies…
Dr. Kai Schulze-Forster, co-founder of CellTrend GmbH, was awarded the title of professor by the Technical University in Wildau. In a ceremonial act Prof. Dr. Ulrike Tippe, president of the TH Wildau, presented the certificate on Wednesday, 26th June 2019. The entire CellTrend Team congratulates Prof. Dr. Kai Schulze-Forster!
On May 17, 2019, the 20th anniversary of CellTrend took place. Numerous cooperation partners, customers and friends found their way to Luckenwalde on this day to celebrate with us. The audience was offered very interesting speeches by renowned scientists. Therefore we would like to thank Prof. Dr. med. Yehuda Shoenfeld (Sheba Medical Center, Tel Aviv),…
Read the abstract of this interesting article: Anti-angiotensin II type 1 receptor (AT1R) antibodies have been associated with allograft rejection. We hypothesized that circulating AT1R antibodies might identify kidney transplant recipients at increased risk of allograft rejection and loss who are not identified by the HLA system. We prospectively enrolled 1845 kidney transplant recipients from…
Abstract of the article: An autoimmune reaction directed against the cardiac b1-adrenergic receptor (beta1-ADR) leading to the generation of autoantibodies (AA) against this G-coupled receptor has been described in patients with heart failure (HF). Agonist-like beta1-ADR-AA are associated with morbidity in HF patients and even predict mortality. Standardised and valid diagnostic tools to detect beta…
The 10th symposium for Clinical Environmental Medicine will take place in Kiel on 22.02.19 and 23.02.19. The topic is: “Exhaustion as a cardinal symptom of inflammatory and non-inflammatory diseases”. In addition to diagnostics, the focus will be on therapy. Flyer
According to the American Cancer Society ovarian cancer is expected to account for over 22,000 new cancer diagnoses and more than 14,000 deaths in 2018 in the US alone. In early stages of the disease, ovarian cancer is nearly asymptomatic. Hence, a large portion of the patients present with clinically advanced stages of ovarian cancer.…
Beta-1-Adrenergic Receptor Antibodies in Acute Coronary Syndrome: Is Less Sometimes More? Cardiovascular diseases are common, accounting for approximately 17.3 million global deaths annually. Substantial evidence exists for numerous risk factors including dyslipidemia, smoking, arterial hypertension, diabetes, and abdominal obesity. Numerous biomarkers have previously been reported in acute coronary syndromes, relating to both inflammation or…
The POTS, CFS/ME, CRPS diagnostic takes place every 14 days in our lab. The next diagnostic will be on January, 23rd 2020. Please fill out the request form completely (important: email address and signature) and attach it to your shipment. Thank you very much!
Have a look at our latest publication in Nature Communication about autoantibodies against GPCR! 2018 Naturecommunication https://www.nature.com/articles/s41467-018-07598-9
